AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities
AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities
Presenter: Rosalyn M. Adam, PhD
--------
13:26
--------
13:26
AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted?
AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted?
Presenter: Vin Gupta, MD, MPA
--------
1:03:44
--------
1:03:44
AUA2025: John K Lattimer Lecture: Telesurgery
AUA2025: John K Lattimer Lecture: Telesurgery
Presenter: Vipul Patel, MD
--------
22:18
--------
22:18
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)
CME Available: auau.auanet.org/node/42040
After participating in this CME activity, participants will be able to:
1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.
2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.
3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.
4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.
5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.
Acknowledgements
Support provided by an independent educational grant from:
Astellas and Pfizer, Inc.
New Zealand